Shanshan Weng

发表

The Role of Hyperthermia in the Multidisciplinary Treatment of Malignant Tumors

Yi Cheng, Shanshan Weng, Linzhen Yu, 2019, Integrative cancer therapies.

Risk of Second Primary Cancers Among Long-Term Survivors of Breast Cancer

Yi Cheng, Shanshan Weng, N. Zhu, 2020, Frontiers in Oncology.

Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review

Shanshan Weng, Mengyuan Yang, Ding Zhang, 2022, Zeitschrift für Gastroenterologie.

Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019

Xinxiang Li, Zhen Zhang, Gong Chen, 2020, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

General treatment for metastatic colorectal cancer: From KEYNOTE 177 study

Xinyu Li, Shanshan Weng, Ying Yuan, 2021, Translational oncology.

CSCO guidelines for colorectal cancer version 2022: Updates and discussions

Shanshan Weng, Suzhan Zhang, Chenyang Ye, 2022, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and its Response to EGFR-TKIs.

Shanshan Weng, N. Zhu, Ying Yuan, 2019, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020

Zhen Zhang, Su-zhan Zhang, Shanshan Weng, 2021, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Immune Checkpoint Inhibitors combined with HER-2 targeted therapy in HER-2 positive Gastroesophageal cancer.

Xinyu Li, Shanshan Weng, Ying Yuan, 2022, Critical reviews in oncology/hematology.

Ferroptosis regulator FANCD2 is associated with immune infiltration and predicts worse prognosis in lung adenocarcinoma

Shanshan Weng, Chenyang Ye, Yier Lu, 2022, Frontiers in Genetics.

Impact of the COVID-19 Epidemic on the Routine Emergency Services in a Tertiary Hospital, China: A Retrospective Cohort Study

Shanshan Weng, H. Nie, Lianjing Liang, 2020, Disaster Medicine and Public Health Preparedness.

REV1: A novel biomarker and potential therapeutic target for various cancers

X. Fang, Shanshan Weng, N. Zhu, 2022, Frontiers in Genetics.

Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors

X. Fang, Shanshan Weng, Linzhen Yu, 2019, Journal of Cancer Research and Clinical Oncology.

Oncotargets and Therapy Dovepress Critical Appraisal of the Role of Gefitinib in the Management of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Shanshan Weng, Ying Yuan, Jian-jin Huang, 2022 .

Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database

Shanshan Weng, Ying Yuan, Hong Shen, 2017, Oncotarget.

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer

Su-zhan Zhang, L. Ding, Shanshan Weng, 2016, Contemporary oncology.

Clinical Characteristics, Treatment, and Prognostic Factors of Patients With Primary Extramammary Paget's Disease (EMPD): A Retrospective Analysis of 44 Patients From a Single Center and an Analysis of Data From the Surveillance, Epidemiology, and End Results (SEER) Database

Shanshan Weng, N. Zhu, Ying Yuan, 2020, Frontiers in Oncology.

Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing

X. Fang, Shanshan Weng, Mengyuan Yang, 2018, Cancer biology & therapy.

Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach

Jinghong Xu, Shanshan Weng, Ying Yuan, 2015, Medicine.

Metronomic chemotherapy in non-small cell lung cancer.

Shanshan Weng, Song Zheng, Y. Shu, 2020, Oncology letters.

Outcomes of surgery for gastric cancer with distant metastases: a retrospective study from the SEER database

Shanshan Weng, Ying Yuan, J. Zhong, 2016, Oncotarget.

Phenotypic Variation and Carbapenem Resistance Potential in OXA-499-Producing Acinetobacter pittii

Yunsong Yu, X. Hua, Yan Chen, 2020, Frontiers in Microbiology.

Emerging patterns and trends in global cancer burden attributable to metabolic factors, based on the Global Burden of Disease Study 2019

Shanshan Weng, N. Zhu, Jia Zheng, 2023, Frontiers in Oncology.

Global burden of tracheal, bronchus, and lung cancer attributable to occupational carcinogens in 204 countries and territories, from 1990 to 2019: results from the global burden of disease study 2019

Shanshan Weng, N. Zhu, Yier Lu, 2023, Annals of medicine.

Identification and prognostic analysis of the cetuximab resistance-related gene REV1 in RAS wild-type metastatic colorectal cancer.

X. Fang, Shanshan Weng, N. Zhu, 2021, American journal of cancer research.

Mechanisms of Hyperthermia Alone or in Combination With Other Therapeutic Methods Mechanisms of Hyperthermia

Yi Cheng, Shanshan Weng, Linzhen Yu, 2019 .

Simultaneous triple primary malignancies, including bladder cancer, lymphoma, and lung cancer, in an elderly male: A case report

Shanshan Weng, Sheng-hao Wu, Ri-Qing Huang, 2022, Open life sciences.

Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study

X. Fang, Jian Wang, Shanshan Weng, 2023, BMC Cancer.

Establishment of predictive models for acute complicated appendicitis during pregnancy—A retrospective case–control study

Shanshan Weng, H. Nie, Zhuo Zhang, 2023, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trial

X. Fang, Jian Wang, Hongfeng Cao, 2023, EClinicalMedicine.

CSCO guidelines for colorectal cancer version 2023: Updates and insights.

Shanshan Weng, Hanguang Hu, Mi Mi, 2023, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Critical appraisal of the role of gefitinib in the management of locally advanced or metastatic non-small cell lung cancer

Shanshan Weng, Ying Yuan, Jian-jin Huang, 2014, OncoTargets and therapy.

Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review Vemurafenib kontrollierte wirksam auf Chemotherapie refraktäres intrahepatisches Cholangiokarzinom mit BRAFV600E-Mutation: ein Fallbericht und eine

Shanshan Weng, Ding Zhang, Mengyuan Yang, 2022 .

CSCO guidelines for metastatic colorectal cancer: personalized medicine in clinical practice

Yuefen Pan, Shanshan Weng, Mengyuan Yang, 2023, Cancer biology & medicine.